Emily Oldshue and Martin Ruhaak Named Law360 Rising Stars in Life Sciences and Private Equity
Mergers & acquisitions and capital markets partner Emily Oldshue and private equity partner Martin Ruhaak were named Law360 Rising Stars for 2022 in Life Sciences and Private Equity, respectively. Law360 annually selects the top lawyers under the age of 40 based on their career accomplishments. The full list of Law360 Rising Stars includes attorneys at 96 law firms across 36 practice areas.
Emily has helped brand-name companies close complex multibillion-dollar transactions and steered cutting-edge capital markets offerings including IPOs and other offerings. Her counsel has been key to biotechnology and pharmaceutical companies raising needed capital to accelerate their growth and to companies seeking to acquire key assets or divest non-core businesses or products.
Emily led Pfizer in its $11.6 billion agreement to acquire Biohaven Pharmaceuticals, the maker of NURTEC ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. The transaction features a pre-closing spin-off of certain of Biohaven’s pipeline assets into a new public company and a novel royalty structure.
Emily also counseled Pfizer in its $6.7 billion acquisition of Arena Pharmaceuticals, a company developing innovative potential therapies for several immuno-inflammatory diseases, and in its $2.2 billion acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Pfizer’s acquisition of Arena was one of the top five biopharmaceutical M&A deals announced in 2021, measured by deal value on data published by PharmaCompass. Pfizer’s acquisition of Trillium was one of the top 10 biopharmaceutical M&A deals announced in 2021, measured by deal value on data published by PharmaCompass.
Marty has fast become a valued and trusted advisor for numerous private equity clients and their portfolio companies based in the United States, Europe and China. Known for his hard work, sound advice and affable disposition, Marty has guided transactions on behalf of The Vistria Group, GHO Capital, Gryphon Investors, PSP Partners, BBH Capital Partners, Baring Private Equity Asia, Centerbridge Partners, Duff & Phelps and NovaQuest Capital Management.
Over the past year, Marty advised private equity clients on a series of ambitious and complex transactions. In January, he advised Singapore-based Baring Private Equity Asia as it closed on a $1.2 billion acquisition of HGS Healthcare, the healthcare services unit of Hinduja Global Solutions, the Indian IT services company while in November 2021 he represented GHO Partners in its purchase of Genesis Research.
In September 2021, Marty also represented Baring Private Equity Asia in the completion of its sale of Lumenis to Boston Scientific, and in July 2021, he counseled Help at Home, a Centerbridge/Vistria portfolio company, in its acquisition of Community Care Systems.